Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism


MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath® (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism that are not adequately controlled with conventional therapy.



Source link

  • Related Posts

    Ongwe Minerals Announces Voluntary Filing of Technical Report

    Qualified Person Read More Source link

    Lululemon reports drop in sales and revenue in second quarter, revises outlook

    Lululemon Athletica Inc. reported a tough second quarter on Thursday as revenue, profits and comparable sales all declined year over year. Read More Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    More trains – iPolitics

    More trains – iPolitics

    Ongwe Minerals Announces Voluntary Filing of Technical Report

    County Championship: Middlesex in control over Lancashire as 19 wickets fall

    County Championship: Middlesex in control over Lancashire as 19 wickets fall

    American automakers urge Congress to ban Chinese vehicle sales in the U.S.

    American automakers urge Congress to ban Chinese vehicle sales in the U.S.

    Today’s NYT Strands Hints, Answers and Help for Sept. 4, #915

    Today’s NYT Strands Hints, Answers and Help for Sept. 4, #915

    The Most Divisive Civilization Game is Completely Free to Play on Steam for One Week

    The Most Divisive Civilization Game is Completely Free to Play on Steam for One Week